Side‐Effect Profile of Serotoninergic Treatments for Parkinson's Disease and L‐DOPA‐induced Dyskinesia in Rats
Conclusions and ImplicationsResults suggest that compounds that indirectly facilitate 5‐HT1A activation, such as citalopram, may be more effective therapeutics than direct 5‐HT1A receptor agonists because they exhibit similar anti‐dyskinesia efficacy, while possessing a lesser side‐effect profile.
Source: British Journal of Pharmacology - Category: Drugs & Pharmacology Authors: D. Lindenbach, N. Palumbo, C. Y. Ostock, N. Vilceus, M. M. Conti, C. Bishop Tags: Research Paper Source Type: research
More News: Buspirone | Celexa | Citalopram | Drugs & Pharmacology | Dyskinesia | Parkinson's Disease